Logotype for Anika Therapeutics Inc

Anika Therapeutics (ANIK) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Anika Therapeutics Inc

Proxy filing summary

28 Apr, 2026

Voting matters and shareholder proposals

  • Election of three Class III Directors: Gary P. Fischetti, John B. Henneman III, and Stephen D. Griffin, all recommended by the board.

  • Ratification of Deloitte & Touche LLP as independent registered accounting firm for fiscal year ending December 31, 2026.

  • Advisory vote on executive compensation (say-on-pay) is included.

  • Approval sought for amendments to the 2017 Omnibus Incentive Plan and the 2021 Employee Stock Purchase Plan.

  • Other business may be addressed as appropriate at the meeting or any adjournment.

Board of directors and corporate governance

  • Board recommends all director nominees for election to Class III positions.

Executive compensation and say-on-pay

  • Advisory vote on named executive officer compensation is on the agenda.

  • Amendments to incentive and employee stock purchase plans are proposed for approval.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more